Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25mg IVB and had a minimum follow-up of 60months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60months. Mean CMT decreased from 403.5±142.2μm at baseline to 313.7±117.7μm over 5years follow-up (p≤0.0001). Conclusions The early visual gains due to IVB were not maintained 5years after treatment.
- Posterior Chamber
- Treatment Medical
ASJC Scopus subject areas
- Sensory Systems
- Cellular and Molecular Neuroscience